Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | +2.80% | -.--% | +122.73% |
May. 30 | Ocean Biomedical Gets Nasdaq Noncompliance Notice; Shares Down | MT |
Apr. 15 | Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 |
---|---|---|
Capitalization 1 | 105.9 | 110.2 |
Enterprise Value (EV) 1 | 106 | 111.4 |
P/E ratio | -2.8 x | -10.5 x |
Yield | - | - |
Capitalization / Revenue | - | - |
EV / Revenue | - | - |
EV / EBITDA | - | - |
EV / FCF | 4,743,213 x | 20,859,169 x |
FCF Yield | 0% | 0% |
Price to Book | -26.2 x | -16.8 x |
Nbr of stocks (in thousands) | 10,600 | 10,600 |
Reference price 2 | 9.990 | 10.40 |
Announcement Date | 4/11/22 | 3/31/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
Net sales | - | - | - | - |
EBITDA | - | - | - | - |
EBIT 1 | -0.232 | -1.652 | -62.34 | -16.12 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.232 | -1.653 | -62.34 | -17.36 |
Net income 1 | -0.232 | -1.653 | -62.34 | -17.36 |
Net margin | - | - | - | - |
EPS 2 | -0.0133 | -0.0947 | -3.565 | -0.9921 |
Free Cash Flow | - | - | 22.33 | 5.285 |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 3/5/21 | 3/5/21 | 4/11/22 | 3/31/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 |
---|---|---|---|
Net sales 1 | - | - | - |
EBITDA | -5.223 | -2.68 | - |
EBIT 1 | -5.223 | -2.68 | -2.655 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -67.4 | -13.03 | -14.09 |
Net income 1 | -67.4 | -13.03 | -14.09 |
Net margin | - | - | - |
EPS 2 | -2.720 | -0.4900 | -0.5300 |
Dividend per Share | - | - | - |
Announcement Date | 5/24/23 | 8/14/23 | 4/15/24 |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
Net Debt | - | - | 0.12 | 1.19 |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | 22.3 | 5.28 |
ROE (net income / shareholders' equity) | - | 156% | 1,459% | 199% |
ROA (Net income/ Total Assets) | - | - | -16,759% | -1,049% |
Assets 1 | - | - | 0.372 | 1.655 |
Book Value Per Share 2 | -0.0100 | -0.1100 | -0.3800 | -0.6200 |
Cash Flow per Share | - | - | 0 | 0 |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 3/5/21 | 3/5/21 | 4/11/22 | 3/31/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+122.73% | 49.55M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- OCEA Stock
- Financials Ocean Biomedical, Inc.